The ALK, ROS1 and RET kinase fusion are crucial biomarkers that can predict the function of tyrosine kinase inhibitors (TKIs) in the non-small-cell-lung cancer (NSCLC). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.